Aclaris Therapeutics (NASDAQ:ACRS) Shares Gap Up to $14.33
Aclaris Therapeutics (NASDAQ:ACRS) Shares Gap Up to $14.33
Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Rating) shares gapped up prior to trading on Friday . The stock had previously closed at $14.33, but opened at $14.81. Aclaris Therapeutics shares last traded at $14.85, with a volume of 333,935 shares traded.
Aclaris治疗公司(纳斯达克代码：ACRS-GET评级)的股价在周五交易前大幅上涨。该股此前收盘报14.33美元，开盘报14.81美元。Aclaris Treateutics的股票尾盘报14.85美元，成交量为333,935股。
Analyst Ratings Changes
分析师评级发生变化
Several research firms have recently issued reports on ACRS. StockNews.com began coverage on Aclaris Therapeutics in a research report on Wednesday, October 12th. They issued a "sell" rating for the company. SVB Leerink reissued an "outperform" rating on shares of Aclaris Therapeutics in a research report on Tuesday, November 8th. Stifel Nicolaus started coverage on Aclaris Therapeutics in a research report on Tuesday, December 13th. They issued a "buy" rating and a $29.00 target price for the company. Finally, The Goldman Sachs Group initiated coverage on Aclaris Therapeutics in a research report on Thursday, December 1st. They issued a "buy" rating and a $25.00 target price for the company. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $28.67.
几家研究公司最近发布了关于ACRS的报告。StockNews.com在10月12日星期三的一份研究报告中开始报道Aclaris治疗公司。他们对该公司的评级为“卖出”。SVB Leerink在11月8日(星期二)的一份研究报告中重新发布了对Aclaris Treeutics股票的“跑赢大盘”评级。Stifel Nicolaus于12月13日星期二在一份研究报告中开始报道Aclaris治疗公司。他们对该公司的评级为“买入”，目标价为29.00美元。最后，高盛在12月1日星期四的一份研究报告中发起了对Aclaris治疗公司的报道。他们对该公司的评级为“买入”，目标价为25美元。一名投资分析师对该股的评级为卖出，六名分析师对该股的评级为买入。根据MarketBeat.com的数据，该公司目前的共识评级为“适度买入”，共识目标价为28.67美元。
Aclaris Therapeutics Stock Performance
Aclaris Treateutics股票表现
The company has a fifty day moving average of $16.04 and a two-hundred day moving average of $16.07. The company has a market cap of $936.90 million, a PE ratio of -10.89 and a beta of 0.57.
该公司的50日移动均线切入位16.04美元，200日移动均线切入位16.07美元。该公司市值为9.369亿美元，市盈率为-10.89，贝塔系数为0.57。
Insider Transactions at Aclaris Therapeutics
Aclaris治疗公司的内幕交易
In related news, Director Neal Walker sold 25,000 shares of Aclaris Therapeutics stock in a transaction that occurred on Tuesday, January 3rd. The stock was sold at an average price of $15.25, for a total transaction of $381,250.00. Following the completion of the transaction, the director now directly owns 1,220,763 shares in the company, valued at $18,616,635.75. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, insider Joseph Monahan sold 5,000 shares of Aclaris Therapeutics stock in a transaction that occurred on Thursday, December 15th. The stock was sold at an average price of $15.88, for a total value of $79,400.00. Following the sale, the insider now directly owns 96,386 shares of the company's stock, valued at $1,530,609.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Neal Walker sold 25,000 shares of Aclaris Therapeutics stock in a transaction that occurred on Tuesday, January 3rd. The stock was sold at an average price of $15.25, for a total value of $381,250.00. Following the completion of the sale, the director now directly owns 1,220,763 shares in the company, valued at $18,616,635.75. The disclosure for this sale can be found here. Company insiders own 6.70% of the company's stock.
在相关新闻中，董事尼尔·沃克在1月3日(星期二)的一笔交易中出售了25,000股Aclaris治疗公司的股票。该股以15.25美元的平均价格出售，总成交金额为381,250.00美元。交易完成后，董事现在直接拥有该公司1220,763股股份，价值18,616,635.75美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，该文件可以通过此超链接。在其他消息方面，内部人士约瑟夫·莫纳汉在12月15日星期四的一笔交易中出售了5,000股Aclaris治疗公司的股票。这只股票的平均售价为15.88美元，总价值为79,400.00美元。出售后，这位内部人士现在直接持有该公司96,386股股票，价值1,530,609.68美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，该文件可通过此超链接。此外，董事尼尔·沃克在1月3日(星期二)的一笔交易中出售了25,000股Aclaris治疗公司的股票。股票以15.25美元的平均价格出售，总价值为381,250.00美元。出售完成后，董事现在直接拥有该公司1220,763股票，价值18,616,635.75美元。关于这次销售的披露可以找到这里。公司内部人士持有该公司6.70%的股份。
Hedge Funds Weigh In On Aclaris Therapeutics
对冲基金入股Aclaris Treeutics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in ACRS. Wellington Management Group LLP raised its position in Aclaris Therapeutics by 3.4% in the first quarter. Wellington Management Group LLP now owns 5,730,253 shares of the biotechnology company's stock valued at $98,789,000 after purchasing an additional 190,985 shares during the period. BlackRock Inc. increased its holdings in Aclaris Therapeutics by 3.0% during the 3rd quarter. BlackRock Inc. now owns 4,810,298 shares of the biotechnology company's stock worth $75,714,000 after purchasing an additional 140,382 shares during the period. Vanguard Group Inc. boosted its position in shares of Aclaris Therapeutics by 4.2% during the 3rd quarter. Vanguard Group Inc. now owns 2,931,709 shares of the biotechnology company's stock worth $46,145,000 after acquiring an additional 118,024 shares in the last quarter. Commodore Capital LP boosted its position in shares of Aclaris Therapeutics by 4.1% during the 2nd quarter. Commodore Capital LP now owns 2,410,622 shares of the biotechnology company's stock worth $33,652,000 after acquiring an additional 95,974 shares in the last quarter. Finally, Point72 Asset Management L.P. boosted its position in shares of Aclaris Therapeutics by 6.9% during the 3rd quarter. Point72 Asset Management L.P. now owns 1,853,251 shares of the biotechnology company's stock worth $29,170,000 after acquiring an additional 119,351 shares in the last quarter. Institutional investors and hedge funds own 95.33% of the company's stock.
一些机构投资者和对冲基金最近增持或减持了ACRS的股份。惠灵顿管理集团LLP在第一季度将其在Aclaris Treeutics的头寸提高了3.4%。惠灵顿管理集团现在拥有5,730,253股这家生物技术公司的股票，价值98,789,000美元，在此期间又购买了190,985股。贝莱德股份有限公司在第三季度增持了Aclaris治疗公司的股份3.0%。贝莱德股份有限公司在此期间增持了140,382股，目前持有这家生物技术公司4,810,298股股票，价值75,714,000美元。先锋集团(Vanguard Group Inc.)在第三季度将其在Aclaris Treeutics的股票头寸增加了4.2%。先锋集团(Vanguard Group Inc.)在上个季度增持了118,024股后，目前持有这家生物技术公司2,931,709股股票，价值46,145,000美元。Commodore Capital LP在第二季度将其在Aclaris Treeutics的股票头寸增加了4.1%。Commodore Capital LP现在拥有这家生物技术公司2,410,622股股票，价值33,652,000美元，上个季度又购买了95,974股。最后，Point72 Asset Management L.P.在第三季度将其在Aclaris Treeutics的股票头寸增加了6.9%。Point72 Asset Management L.P.在上个季度额外收购了119,351股后，现在拥有1,853,251股这家生物技术公司的股票，价值29,170,000美元。机构投资者和对冲基金持有该公司95.33%的股票。
Aclaris Therapeutics Company Profile
Aclaris治疗公司简介
(Get Rating)
(获取评级)
Aclaris Therapeutics, Inc operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through the Therapeutics and Contract Research segments.
Aclaris治疗公司是一家皮肤科医生领导的生物制药公司，致力于识别、开发和商业化新药，以满足医疗和美容皮肤病和免疫学方面的需求。它通过治疗和合同研究部门开展业务。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on Aclaris Therapeutics (ACRS)
- MarketBeat Week in Review – 1/30 – 2/3
- Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
- Zimmer Biomet Beats on Earnings, Growth May be Priced In
- AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
- Ford Stock Going Forward After Big Earnings Flop
- 免费获取StockNews.com关于Aclaris治疗公司(ACRS)的研究报告
- 市场回顾周-1/30-2/3
- 细价股值得吗？你应该投资细价股吗？
- Zimmer Biomet盈利节节攀升，增长可能被计入价格
- 人工智能软件制造商EPAM号称科技板块涨幅最大
- 福特股票在盈利大幅下滑后继续前进
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Aclaris治疗日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Aclaris治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。